Skip to main content

Breakthrough Therapy Designation granted to Global Blood Therapeutics

The Food and Drug Administration granted Breakthrough Therapy Designation to Global Blood Therapeutics Inc.'s (Nasdaq: GBT) voxelotor to treat sickle cell disease sending the stock price soaring $7.55 to close at $47.15.



Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.